7-amino-4-hydroxy-2-naphthalenesulfonic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
7-amino-4-hydroxy-2-naphthalenesulfonic acid : An aminonaphthalenesulfonic acid that is 2-naphthalenesulfonic acid substituted by an amino group at position 7 and a hydroxy group at position 4 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6868 |
| CHEMBL ID | 220259 |
| CHEBI ID | 87316 |
| SCHEMBL ID | 154124 |
| MeSH ID | M0271514 |
| Synonym |
|---|
| 2-amino-5-naphthol-7-sulfonic acid |
| i acid |
| nsc7556 |
| nsc8631 |
| isogamma acid |
| nsc-8631 |
| kyselina i |
| 7-amino-4-hydroxy-2-naphthalenesulfonic acid |
| mls002638012 , |
| wln: l66j bq dswq hz |
| j acid |
| aminonaphthol sulfonic acid j |
| kyselina 2-amino-5-naftol-7-sulfonova |
| nsc-7556 |
| 2-naphthalenesulfonic acid, 7-amino-4-hydroxy- |
| 87-02-5 |
| nsc31510 |
| nsc-31510 |
| 7-amino-4-hydroxynaphthalene-2-sulfonic acid |
| 7-amino-4-hydroxy-naphthalene-2-sulfonic acid |
| ccris 8989 |
| brn 2217192 |
| einecs 201-718-9 |
| kyselina i [czech] |
| kyselina 6-amino-1-naftol-3-sulfonova [czech] |
| 7-amino-4-hydroxynaphthalene-2-sulphonic acid |
| nsc 31510 |
| kyselina 2-amino-5-naftol-7-sulfonova [czech] |
| 6-amino-1-naphthol-3-sulfonic acid |
| A0370 |
| smr001547516 |
| CHEMBL220259 , |
| chebi:87316 , |
| bdbm50206424 |
| cid_6868 |
| NCGC00249193-01 |
| HMS3085K07 |
| dtxsid7026520 , |
| tox21_303310 |
| dtxcid206520 |
| cas-87-02-5 |
| NCGC00257232-01 |
| tox21_202232 |
| NCGC00259781-01 |
| 9a1iu1c93l , |
| kyselina 6-amino-1-naftol-3-sulfonova |
| unii-9a1iu1c93l |
| ec 201-718-9 |
| FT-0611181 |
| AKOS015854951 |
| SCHEMBL154124 |
| 1-hydroxy-6-aminonaphthalene-3-sulphonic acid |
| KYARBIJYVGJZLB-UHFFFAOYSA-N |
| 2-amino-5-hydroxynaphthalene-7-sulfonic acid |
| 7-amino-4-hydroxy-2-naphthalenesulphonic acid |
| W-104047 |
| 1-naphthol-3-sulfonic acid, 6-amino- |
| 6-amino-1-hydroxy-3-naphthalenesulfonic acid |
| 2-amino-5-hydroxy-7-naphthalenesulfonic acid |
| 1-hydroxy-3-sulfo-6-aminonaphthalene |
| 3-amino-8-naphthol-6-sulfonic acid |
| 3-amino-8-hydroxy-6-sulfonaphthalene |
| 3-amino-6-sulfo-8-naphthol |
| 6-amino-1-hydroxy-3-sulfonaphthalene |
| 1-hydroxy-6-amino-3-naphthalenesulfonic acid |
| 3-amino-8-hydroxy-6-naphthalenesulfonic acid |
| 6-amino-3-sulfo-1-naphthol |
| 7-amino-4-hydroxy-2-naphthalenesulfonic acid, technical, >=90% (t) |
| j-saure |
| Q259271 |
| AS-17223 |
| 6-amino-1-naphthol-3-sulfonic acid;2-amino-5-naphthol-7-sulfonic acid; 7-amino-4-hydroxy-2-naphthalene sulphonic acid |
| 6-amino-1-hydroxynaphthalene-3-sulfonic acid |
| H11790 |
| A915651 |
| CS-0187248 |
| 7-amino-4-hydroxynaphthalene-2-sulfonicacid |
| PD183075 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| aminonaphthalenesulfonic acid | A naphthalenesulfonic acid having at least one amino substituent. |
| naphthols | Any hydroxynaphthalene derivative that has a single hydroxy substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 54.0747 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 31.6228 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 50.9100 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 8.7283 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 3.9811 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2436 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 12.3221 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 11.1575 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 2.8577 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 52.1194 | 6.3096 | 27.0990 | 79.4328 | AID602179 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.6245 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 21.9072 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 15.8155 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 3.0945 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.5028 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 34.1628 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 41.3040 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743191 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 2.4361 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 13.9833 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 28.9554 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 9.2000 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 11.2202 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 55.3183 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.9125 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| snurportin-1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 4.8965 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 60.1198 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 5.6234 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 8.9125 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 17.4488 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 47.9617 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 31.6228 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 4.4397 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 47.9617 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.0795 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 14.1254 | 0.0757 | 8.4742 | 29.0628 | AID602233 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 (µMol) | 66.0000 | 4.9100 | 23.7029 | 76.1900 | AID602259; AID602260 |
| tyrosine-protein phosphatase non-receptor type 11 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 1.0400 | 0.1600 | 3.3759 | 9.8800 | AID602367 |
| dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 3.4300 | 0.4000 | 9.3610 | 90.0000 | AID602374 |
| tyrosine-protein phosphatase non-receptor type 5 isoform a | Homo sapiens (human) | IC50 (µMol) | 56.7000 | 4.1700 | 12.5457 | 19.0000 | AID602372; AID624207 |
| Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 9.4400 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
| Tat | Human immunodeficiency virus 1 | IC50 (µMol) | 47.9550 | 0.9960 | 39.8009 | 100.0000 | AID1117361 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 9.4400 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 928.0000 | 0.0003 | 0.3907 | 5.4000 | AID280501 |
| RmtA | Aspergillus nidulans | IC50 (µMol) | 590.0000 | 5.9000 | 5.9000 | 5.9000 | AID280502 |
| Protein arginine N-methyltransferase 1 | Homo sapiens (human) | IC50 (µMol) | 928.0000 | 0.2500 | 3.6167 | 9.4000 | AID280501 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 2.1500 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
| histone-lysine N-methyltransferase NSD2 isoform 1 | Homo sapiens (human) | AC50 | 6.4900 | 0.2930 | 7.3070 | 19.4400 | AID1053173 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID280501 | Inhibition of human recombinant GST-PRMT1 expressed in BL21 cells | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. |
| AID280502 | Inhibition of Aspergillus nidulans recombinant GST-RmtA expressed in BL21 cells | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||